Literature DB >> 9694774

Anticoagulation may be beneficial in high risk factor V Leiden carriers.

T Baglin, C Baglin, K Brown, R Luddington.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694774      PMCID: PMC1113688     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.

Authors:  F P Sarasin; H Bounameaux
Journal:  BMJ       Date:  1998-01-10

2.  Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group.

Authors:  C Baglin; K Brown; R Luddington; T Baglin
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

3.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

4.  Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.

Authors:  M Levine; J Hirsh; M Gent; A Arnold; D Warr; A Falanga; M Samosh; V Bramwell; K I Pritchard; D Stewart
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

5.  Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.

Authors:  L Poller; A McKernan; J M Thomson; M Elstein; P J Hirsch; J B Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.